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Abstract 
In patients with dysfunctions of the Ca2+ channel ORAI1, stromal interaction molecule 1 
(STIM1) or integrin-regulating kindlin-3 (FERMT3), severe immunodeficiency is 
frequently linked to abnormal platelet activity. In this paper, we studied in nine rare 
patients, including relatives, with confirmed genetic mutations of ORAI1, STIM1 or 
FERMT3, platelet responsiveness by multi-parameter assessment of whole blood 
thrombus formation under high-shear flow conditions. In platelets isolated from 5 out of 6 
patients with ORAI1 or STIM1 mutations, store-operated Ca2+ entry (SOCE) was 
(in)completely defective compared to control platelets. Parameters of platelet adhesion 
and aggregation on collagen microspots were impaired for 4/6 patients, in part related to 
a low platelet count. For 4 patients, platelet adhesion/aggregation and procoagulant 
activity on VWF/rhodocytin and VWF/fibrinogen microspots were impaired, 
independently of platelet count and partly correlated with SOCE deficiency. 
Measurement of thrombus formation at low shear rate confirmed a larger impairment of 
platelet functionality in the ORAI1 patients than in the STIM1 patient. For 3 
patients/relatives with a FERMT3 mutation, all parameters of thrombus formation were 
strongly reduced regardless of the microspot. Bone marrow transplantation, required by 
two patients, resulted in overall improvement of platelet function. We concluded that 
multiparameter assessment of whole-blood thrombus formation, in a surface-dependent 
way, can detect: (i) additive effects of low platelet count and impaired platelet 
functionality; (ii) aberrant ORAI1-mediated Ca2+ entry; (iii) differences in platelet 
activation between patients carrying the same ORAI1 mutation; (iv) severe platelet 
function impairment linked to a FERMT3 mutation and bleeding history. 
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Introduction 
Severe, genetically linked immunodeficiency can be accompanied by platelet function 
defects, especially in case of rare mutations in the ORAI1, STIM1 and FERMT3 genes 
on platelet properties, in spite of the solid evidence for a role of the mouse orthologues 
in arterial thrombosis. 
In platelets and other blood cells, stromal interaction molecule 1 (STIM1) acts as 
a major Ca2+ sensor located in the endoplasmic reticulum. Upon lowering of the reticular 
Ca2+ concentration, it assembles with the ORAI1 Ca2+ (ICRAC) channels in the plasma 
membrane to mediate store-operated Ca2+ entry (SOCE).1-4 The conventional test for 
SOCE (i.e., for STIM1 and ORAI1 activity) hence is to provoke depletion of the STIM1-
linked Ca2+ store with the endoplasmic Ca2+-ATPase inhibitor thapsigargin, and then 
measure Ca2+ entry through ORAI1 channels upon addition of extracellular CaCl2.5, 6 
Both ORAI1 and STIM1 have non-redundant roles in the patrolling and defense 
functions of white blood cells. In platelets, ORAI1 as well as STIM1 are considered to 
enhance the Ca2+ signal generation, especially induced by protein tyrosine kinase-linked 
receptors, such as glycoprotein VI (GPVI). In mouse, both ORAI1 and STIM1 are 
implicated in hemostasis and arterial thrombus formation.7-10 Murine knockout studies 
have indicated that the ORAI1-STIM1 Ca2+ signaling contributes to multiple platelet 
activation processes, such as adhesiveness via integrin activation, granule release, 
aggregation of platelets, and procoagulant activity.8, 11, 12 However, in humans, the 
consequences of defective ORAI1 or STIM1 activity in platelets have only poorly been 
investigated. 
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In humans, dysfunctional mutations in the ORAI1 or STIM1 genes are very rare.13 
The patients described with such mutations usually suffer from severe 
immunodeficiency, congenital myopathy, ectodermal dysplasia or other Ca2+-linked 
abnormalities.14-16 The immune deficiency can be attributed to the loss-of-function of 
leukocyte and lymphocyte subsets. Given the severity of the symptoms often already at 
a young age, these patients are commonly treated by allogeneic hematopoietic stem cell 
transplantation. The few patients described do not have an overt bleeding history, 
although they may periodically show autoimmune thrombocytopenia.16  
Leukocyte adhesion deficiency type III (LAD-III) forms another severe immune 
disease, in this case accompanied by epistaxis or petechiae. It is associated with 
dysfunctional mutations in the FERMT3 gene of the integrin-regulation protein, kindlin-
3.13 LAD-IIII patients present with normal platelet count, but impaired platelet adhesion, 
which may explain the bleeding symptoms.17, 18 Also these patients may require 
hematopoietic stem cell transplantation during childhood.19 
Recently, we developed a microspot-based assay for multiparameter assessment 
of whole-blood thrombus formation under flow conditions.20 This assay proved to be 
valuable to characterize platelet count and function abnormalities in patients with a 
variety of genetic bleeding disorders. Here, we used this integrative method to 
investigate overall platelet functions in nine patients with severe immunodeficiencies, 
including parents, with a confirmed dysfunctional mutation in ORAI1, STIM1 or FERMT3. 
For two patients, we also investigated effects of bone marrow transplantation. The 
results suggest a variable phenotypic penetrance on platelet properties in patients and 
relatives carrying those mutations. 
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Methods 
Patients and controls 
Blood was drawn from patients and healthy controls after full informed consent (Helsinki 
declaration). The studies were approved by the local Medical Ethics Committees. 
Healthy controls had normal blood cell counts, were devoid of anti-platelet medication 
for at least 2 weeks, and did not have a known history of bleeding or immunodeficiency. 
Blood samples from patients with immunodeficiency and their parents (all 
genotyped) were collected at the Department of Pediatrics and Adolescent Medicine, 
University Medical Center in Freiburg, and at the Children’s Hospital, University of Ulm 
(Table 1). Simultaneously, blood samples were taken from healthy donors, serving as 
daily travel controls. Relevant patient characteristics, including identified mutations and 
the clinical history are summarized in Table 1. Patient P1 showed homozygosity in the 
R91W mutation in the ORAI1, known to be linked to severe combined immunodeficiency 
and defective T cell Ca2+ signaling.1 Heterozygosity in this mutation was confirmed for 
both parents (P2 and P3). Patient P4 carried a heterozygous G98S mutation in ORAI1, 
which was confirmed in the mother (P5). This mutation is reported to be linked to tubular 
aggregated myopathy-2.21 Patient P6 carried a heterozygous R429C mutation of STIM1, 
which is also linked to T cell immunity.22 Patient P7 suffered from severe 
immunodeficiency, linked to a homozygous R573X mutation in kindlin-3 encoded by the 
FERMT3 gene. The two parents (P8 and P9) were heterozygous for this mutation. Two 
of the patients with severe immunodeficiency, P1 and P7, were eligible for bone marrow 
transplantation. Blood samples in these cases were obtained before and at 2 or 3 
months after transplantation, respectively. The volumes of blood available for 
investigation were limited due to the young age of the patients. 
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Platelet Ca2+ responses 
Rises in cytosolic [Ca2+]i were measured in platelets after loading with Fura-2 
acetoxymethyl ester (2.5 µM) by calibrated ratio fluorometry.23 Data are presented as 
nM increases in cytosolic [Ca2+]i.24 
 
Multiparameter thrombus formation on microspots under flow 
Whole blood thrombus formation was assessed under flow conditions, basically as 
described before.20 In brief, blood samples (0.5 mL) were recalcified in the presence of 
thrombin inhibitors, and perfused over a coverslip coated with three microspots (spot 1: 
type I collagen, spot 2: VWF/rhodocytin, spot 3: VWF/fibrinogen) in a transparent 
parallel-plate perfusion chamber. Perfusion was at high wall-shear rate of 1600 s-1 for 
3.5 min, or at low shear rate of 150 s-1 for 6.0 min. The thrombi formed on the 
microspots were immediately post-stained with FITC-labeled anti-fibrinogen mAb 
(1:100), FITC-anti-CD62P mAb (25 µg/mL) and AF647-annexin A5 (0.25 µg/mL). 
Representative brightfield and fluorescence images were captured from each microspot 
in real-time without fixation. Duplicate runs were performed, whenever possible. 
Analysis of brightfield and fluorescence images, giving 7 parameters per microspot, was 
performed with predefined scripts in Fiji software.25 (Un)supervised heatmaps using 
scaled parameters (range 0-10) of thrombus formation were constructed in R. 
 
 
Statistics 
Significance of differences was determined with the paired sample t test (intervention 
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effects) and by principal component analysis (PCA), using the statistical package for 
social sciences (SPSS, version 11.0). 
 
A detailed description of the methods is available in the Online Supplementary 
Appendix. 
 
Results 
Variable aberrances in SOCE in platelets from patients with ORAI1 or STIM1 
mutations 
Blood samples were obtained from three patients with a mutation in the Ca2+ flux-
regulating proteins ORAI1 or STIM1, as well as from parents carrying the same 
mutation. For comparison, blood samples were also taken from two cohorts of healthy 
subjects, i.e. a group of normal home controls (HC1-12) and a group of normal travel 
controls (C1-6). Using Fura-2-loaded platelets, we first evaluated the alterations in Ca2+ 
signaling in response to the GPVI receptor agonist, convulxin, the PAR receptor agonist, 
thrombin, and the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor, 
thapsigargin. In each case, the platelets were first stimulated with agonist in Ca2+-free 
medium, after which extracellular CaCl2 was added to measure secondary Ca2+ entry. 
In comparison to control platelets, platelets from patient P1, carrying a 
homozygous ORAI191W/W mutation, responded normally to each agonist, but showed a 
substantially reduced Ca2+ entry following stimulation with convulxin but not thrombin 
(Figure 1A-B). Markedly, in the patient's platelets, Ca2+ entry after stimulation with 
thapsigargin - as a default condition for SOCE -, was completely abolished. This pointed 
to a complete absence of the STIM1-ORAI1 pathway, similarly as established for 
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platelets from STIM1- or ORAI1-deficient- mice.7, 8 Flow cytometric evaluation indicated 
that convulxin-stimulated platelets from P1 showed a reduced PS exposure (7±1% vs. 
28±2% for control platelets, mean ± SEM, n=3, P<0.05), but were not altered in integrin 
αIIbβ3 activation or P-selectin expression (P>0.10). Platelets from the patient's parents 
(both with confirmed heterozygosity) were diminished in SOCE, but to a different extent 
(Figure 2). Platelets from the mother (P2) showed a nearly annulled Ca2+ entry, whereas 
platelets from the father (P3) were less severely reduced, when compared to platelets 
from two cohorts of healthy controls. A second blood sample from patient P1 could be 
obtained at 2 months after bone marrow transplantation. In the platelets, we measured 
about 50% recovery in SOCE signal after thapsigargin stimulation (SOCEP1: 22 nM vs. 
SOCEP1-BM: 575 nM). 
 Platelets from a patient (P4), carrying a heterozygous mutation ORAI189G/S in the 
same protein region, responded differently. These platelets displayed a high SOCE 
signal (Ca2+ entry after thapsigargin). In contrast, platelets from parent P5 (also carrying 
the mutation) were greatly reduced in SOCE (Figure 2). This difference was confirmed 
for a second set of blood samples (not shown). A different picture was obtained with 
patient P6 with a heterozygous mutation in STIM1429R/C.22 In these platelets, Ca2+ rises 
evoked by convulxin/CaCl2 or thrombin/CaCl2 were in the normal range, whereas SOCE 
after thapsigargin was completely abolished (Figure 3A-B). 
Phenotypic analysis of platelets was also performed of a LAD-III patient (P7), 
carrying a homozygous FERMT3573X/X mutation, and presenting with immunodeficiency 
and a history of bleeding.26 Flow cytometry indicated near complete inability of integrin 
αIIbβ3 activation in response to receptor agonists, similarly as described for another 
patient carrying this mutation.27 In platelets from the two heterozygous parents (P8, P9), 
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αIIbβ3 integrin activation was in the normal range (not shown). 
 
Lower range blood cell counts in patients with ORAI1, STIM1 or FERMT3 
mutations 
Table 1 provides an overview of the clinical histories of patients including P1-9, and 
furthermore informs on the hematological parameters, determined in freshly isolated 
blood samples. In all patients, with the exception of P1 and P7, platelet counts were 
between 70 and 150 x 109/L, which are slightly below the normal ranges as present in 
both control cohorts. In the majority of patients, also hematocrit levels were in the lower 
range of normal, i.e. between 0.31 and 0.42 L/L. After bone marrow transplantation (2-3 
months), platelet count in P1 and P7 had restored to 74 and 168 x 109/L, respectively. 
 
Different patterns between patients of aberrant whole-blood thrombus formation 
at high shear rate 
To obtain detailed insight into the hemostatic potential of the patients' platelets, whole-
blood samples were used for multiparameter assessment of thrombus formation under 
flow at high wall-shear rate of 1600 s-1. Samples from corresponding control subjects 
(C1-6) and home control subjects (HC1-12) were again used for comparison. This high-
throughput method, previously established,20 allowed simultaneous examination of 
platelet adhesion, aggregation and activation at three microspots: spot 1 with coated 
type I collagen (involving platelet receptors: GPIb-V-IX, GPVI and integrin α2β1); spot 2 
with coated VWF/rhodocytin (receptors GPIb-V-IX and CLEC-2); and spot 3 with coated 
VWF/fibrinogen (receptors GPIb-V-IX and αIIbβ3). From each microspot, microscopic 
brightfield images were recorded to assess platelet adhesion and aggregation 
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(parameters V1-4); in parallel, fluorescence images were recorded in three colors for 
detection of PS exposure, P-selectin expression and αIIbβ3 activation (parameters V5-7). 
 Representative examples of brightfield and fluorescence images from spot 1 are 
shown in Figure 4, for blood samples of control C2 and immunodeficient patients with 
ORAI1 or STIM1 mutation (P1, P4, and P6). Regarding the patient blood samples, the 
images show patterns of platelet adhesion, aggregation and activation that vary from 
from normal to reduced. The same holds for spot 2 (VWF/rhodocytin) and spot 3 
(VWF/fibrinogen) (see below). 
A heatmap was constructed with data from all analyzed images (3 spots × 7 
parameters) for the cohort of 12 normal home controls (HC1-12), the 6 travel controls 
(C1-6), and the 9 individual patients/relatives with mutations in ORAI1 (P1-5), STIM1 
(P6) or FERMT3 (P7-9), in which all values were normalized to a scale of 0-10 per 
parameter (Figure 5A). In the derived subtraction heatmap of Figure 5B, the patient data 
were expressed relative to those from the home controls. This subtraction confirmed an 
overall high similarity between the values of the two control groups (HC1-12 and C1-6), 
with the exception of a parameter reflecting platelet deposition on spot 2. Datasets for 
individual subjects C1-6 were within the normal ranges (not shown). This confirmed the 
usefulness of the multi-parameter test,20 and underscored the quality of the analyzed 
blood samples. For each patient/relative, we arbitrarily set a relevant effect threshold, 
i.e. when outside the range of mean ± 2 SD of the control group (HC1-12). This filter 
produced a 'relevant' subtraction heatmap, indicating distinct patterns of altered 
parameters of thrombus formation for individual patients P1-9 (Figure 5C). 
Overall, Figure 5C underlines that multiple parameters on spot 1 were reduced 
for patients P2-5, whereas especially parameters on spots 2-3 were reduced for patients 
12 
 
P1 and P5. Interestingly, patient P4 carrying the assumed gain-of-function mutation 
ORAI1G98S (but not relative P5 with low SOCE) showed a typical increase in platelet PS 
exposure. For the patient with homozygous FERMT3 mutation (P7), a more severe 
reduction on all three spots was seen in comparison to the two heterozygous relatives 
(P8-9). 
 
Effects of low platelet count 
Considering that whole-blood thrombus formation can be influenced by not only the 
inherited platelet disorder, but also a low platelet count,28 the present heatmaps may 
reflect both platelet-related properties. To examine this in more detail, the subtraction 
heatmap data were extended with values of platelet count and SOCE. Unsupervised 
clustering of the extended dataset indicated that in particular spot 1, parameters (V1-4) 
clustered with platelet count, while spot 2 parameters (V3-5) and PS exposure (Sp1V5, 
Sp2V5) clustered with altered SOCE (Suppl. Figure 1). 
As an alternative approach, we used the primary (non-normalized) data of 
thrombus formation (Sp1-3, V1-7), platelet count and SOCE for principal component 
analysis (PCA). This revealed a similar pattern, in that the majority of spot 1 parameters 
together with platelet count determined component 1, whereas most spot 2 parameters 
determined component 2 (Suppl. Figure 2A). Statistics (Pearson's regression coefficient) 
confirmed a correlation of spot 1 parameters with platelet count, and also a correlation of 
platelet PS exposure (Sp1V5, Sp3V5) with SOCE (Suppl. Figure 2B). 
This information was then used to interpret the alterations in thrombus formation 
for individual patients (see clustered heatmap of Suppl. Figure 1). Concerning the 
patient (P1) with homozygous R91W mutation in ORAI1, with normal platelet count (207 
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x 109/L) and near abolished SOCE, thrombus formation was near normal on spot 1 
(collagen), but markedly reduced on spot 2 (VWF/rhodocytin) and spot 3 
(VWF/fibrinogen). The impaired Ca2+ signal was linked to a low PS exposure on all spots 
(Suppl. Table1). On the other hand, for the patients P2 and P3 with heterozygous R91W 
mutation in ORAI1 (relatively low platelet counts of 115-156 x 109/L, and 20-60% of 
normal SOCE, respectively), especially parameters for spot 1 were below normal, with a 
reduced PS exposure. 
Concerning patients P4 and P5 heterozygous for the G98S mutation in ORAI1 
(low platelet counts of 70 and 114 x 109/L; 100% and 30% of normal SOCE, 
respectively), thrombus formation on spot 1 was reduced, while parameters of thrombus 
formation on spots 2-3 (including PS exposure) were only reduced for patient P5. In P4 
(but not P5) a gain-of-function of Ca2+ channel activity was apparent from an increased 
PS exposure on spots 2-3. For patient P6, heterozygous for the R429C mutation in 
STIM1, thrombus formation on spot 1 (collagen) was normal in spite of the abolished 
SOCE. Together, this underlined the idea that a low platelet count rather than altered 
SOCE determines the thrombus formation on collagen, but not on the other surfaces. 
Control experiments with reconstituted blood confirmed that, for control donors, 
lowering of the platelet count to 100 x 109/L had a minor effect on particular parameters 
of thrombus formation limited to spot 1, whereas lowering to 50 x 109/L affected 
thrombus formation on all spots 1-3 (Suppl. Figure 3). Taken together with the predictive 
effect of platelet count in the principal component analysis, this suggest that a relatively 
low count affects thrombus formation under flow more severely when combined with a 
reduced platelet functionality. 
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Patterns of aberrant whole-blood thrombus formation at low shear rate 
Using remaining samples from patients/relatives P1-6, we further performed whole-
blood flow measurements at a low shear rate of 150 s-1. Subtraction heatmap analysis of 
the normalized parameter values, in comparison to control data from HC1-12 cohort, 
indicated for all patients with ORAI1 mutations (P1-5) a consistent pattern of reduced 
thrombus formation parameters on spot 1 (Suppl. Figure 4A-C). In particular for patients 
P2 and P3, makers of platelet activation appeared to be reduced (PS exposure, P-
selectin expression and αIIbβ3 activation). Again, for patient P6 with STIM1 mutation, 
most parameters were unchanged. 
Principal component analysis of the low shear data again pointed to a linkage of 
spot 1 parameters with platelet count and a linkage of Sp1V5 (PS exposure) with SOCE 
activity (Suppl. Figure 5A-B). 
 
Partial recovery of whole-blood thrombus formation after bone marrow 
transplantation 
Blood samples from two patients were also obtained after bone marrow transplantation 
(P1 after 2 months, P7 after 3 months), and employed for platelet activation and 
thrombus formation studies. Transplantation of patient P1 led to a partially recovered 
SOCE from 20 to 60% of normal (Figure 2). After transplantation, parameters of 
thrombus formation were particularly reduced on spot 1 (paralleling a reduction in 
platelet count from 207 to 74 x 109/L), but were unchanged for spot 2, and enhanced for 
spot 3 (Figure 6). Transplantation of patient P7 resulted in an overall improvement of 
most parameters on all spots (platelet count changing from 182 to 168 x 109/L). 
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Discussion 
In the present study, we used a multiparameter test of whole-blood thrombus formation 
under flow conditions, as a proxy measurement of hemostatic activity,20 to characterize 
quantitative and qualitative platelet abnormalities in rare patients and their relatives with 
severe immunodeficiencies, linked to signaling protein defects and mutations in the 
ORAI1, STIM1 and FERMT3 genes. So far, functional effects of the ORAI1 and STIM1 
mutations have only been described for human immune cells or cell lines. Hence, the 
present data are the first to report on comparative alterations in platelet SOCE and 
platelet functions in as many as nine genotyped patients/relatives. 
 
Aberrations in SOCE accompanied by mutations in ORAI1 or STIM1 
Earlier work with bone marrow chimeric mice with megakaryocytic deficiency in Orai1 or 
Stim1 demonstrated a prominent role of these Ca2+-entry regulating proteins in platelet 
calcium homeostasis and activation, including PS exposure.11, 29 Our human data are 
compatible with these findings in that SOCE after thapsigargin or GPVI stimulation 
appeared to be impaired in platelets from patient P1 with a homozygous ORAI1W/W 
mutation. A similar impairment of SOCE has been reported in platelets from Orai1R93W 
mice, i.e. a loss-of-function mutation orthologous to the human ORAI1 R91W variant.29 
Platelets from the latter mice showed a defect in Ca2+ fluxes and other responses, when 
triggered with low concentrations of (thrombin or collagen) receptor agonists. These 
platelets displayed normal aggregation under flow conditions, but a decreased 
procoagulant activity (PS exposure).29 
Relatives P2 and P3, heterozygous for the R91W mutation, showed about 20-
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50% residual SOCE activity, which is compatible with co-expression of the non-mutated 
allele in the platelets. Interestingly, Ca2+ entry after thrombin stimulations remained 
unaffected in patients/relatives P1-3, which is explained by involvement of the SOCE-
independent Ca2+ entry mechanism through TRPC6 channels.30  
On the other hand, the R98S mutation in ORAI1, with assumed gain-of-function,31 
carried by patient P4, was not accompanied by altered SOCE activity after thapsigargin 
or GPVI stimulation, whereas SOCE was substantially reduced in the relative P5 
(confirmed in two independent blood samples). The difference in SOCE activity between 
P4 and P5 might be explained by a different 'penetration' of the mutated allele in ORAI1 
expression in megakaryocytes and platelets. However, an alternative explanation is the 
presence of other modifying genetic or acquired factors between P4 and P5, with 
possible effects on platelet SOCE activity, on which we can only speculate. 
Concerning patient P6 with a heterozygous R429C mutation in STIM1, Ca2+ entry 
in platelets was impaired after thapsigargin, but not after GPVI or PAR1/4 stimulation. In 
mammalian cell lines, the R429 mutation modulates the C-terminal oligomerization and 
puncta formation of STIM1 with ORAI1.32 Our results suggest that, in platelets, this 
mutation strongly inhibits the interaction of STIM1 with ORAI1 after full Ca2+ store 
depletion, such as provoked by thapsigargin. 
 
Altered platelet functions in thrombus formation accompanied by mutations in 
ORAI1, STIM1 or FERMT3 
Previous murine studies have pointed out that deficiency in platelet ORAI1 or STIM1 led 
to a moderately reduced collagen-dependent thrombus formation with minimal effect on 
bleeding,8, 11 whereas murine deficiency in FERMT3 (kindlin-3) resulted in impaired 
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thrombus formation and a clear bleeding phenotype.33 Furthermore, both ORAI1-
deficient and ORAI1R93W mouse platelets were found to be partly defective in 
procoagulant activity (PS exposure), along with the annulled SOCE activity.8, 11, 29 
 In the present study, we observed even more variable platelet phenotypes in the 
nine patients/relatives with a mutation in ORAI1, STIM1 or FERMT3. Heatmap analysis 
indicated extensive but distinct patterns of reduced thrombus formation between 
patients, compared to blood from cohorts of healthy control subjects. Blood analysis 
further indicated that most patients/relatives carrying such a mutation had platelet 
counts below or near the lower range of normal. Low platelet count was found to 
correlate with low thrombus formation parameters, especially on spot 1. By comparison 
with flow studies using blood from healthy controls at lower counts, it appears that mild 
thrombocytopenia can lead to a more severe reduction in thrombus formation if 
combined with lower platelet functionality. Mild thrombocytopenia for patients with a 
loss-of-function mutation in ORAI1 or STIM1 has been reported before.16 So far, 
published papers on patients with a FERMT3 mutation do not report on 
thrombocytopenia.26, 27  
Because of the relatively large number of patients in our study, we were able to 
separate the thrombus formation parameters linked to qualitative or quantitative platelet 
defects. Both unsupervised clustering of the heatmap data and principal component 
analysis of the raw data indicated that mostly thrombus parameters on spot 1 (collagen; 
platelet receptors GPIb-V-IX, GPVI, α2β1) showed a dependency on platelet count, 
whereas those of spot 2 (VWF/rhodocytin; receptors GPIb-V-IX, CLEC-2) and spot 3 
(VWF/fibrinogen; receptors GPIb-V-IX, αIIbβ3) were not dependent of platelet count. 
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Markedly, this was true for both the high-shear and low-shear flow tests. An explanation 
for this finding is that, with collagen as a relatively strong agonist for GPVI, on spot 1 
platelet delivery (thus, count) rather than platelet activation is a limiting factor for 
thrombus-forming parameters. In contrast, the immobilized ligands of spots 2-3, being 
less platelet-stimulating, may more rely on full platelet activation including normal SOCE 
and αIIbβ3 integrin activation. Correlation analysis also indicated that PS exposure was a 
key parameter linked to SOCE, in agreement with earlier mouse data.10, 11 
 
Improved platelet functions after bone marrow transplantation 
Bone marrow transplantation of patient P1 (ORAI1W/W), 2 months before, resulted in 
improved SOCE activity and normalized thrombus formation on spot 3 but not on spot 1 
(linked to a low platelet count). Transplantation of P7 (FERMT3X/X), 3 months before, led 
to an overall improvement of thrombus formation parameters (at normal platelet count). 
The partial restoration of platelet count at 2 months post-transplantation is compatible 
with reports that a full normalization can take several months.26, 34  
 
Conclusive remarks 
In Table 2, based on the relevant differential analysis of thrombus formation parameters 
(see Figure 5C), a summative overview is given per patient of alterations in: platelet 
adhesion/aggregation, integrin activation/secretion and procoagulant activity (phases 1-
3). This approach is based on the rationale that this whole-blood flow assay senses 
additive effects of low platelet count and impaired platelet functionality. Table 2 shows 
for all patients/relatives with ORAI1 (R91W) mutation an overall defect in 
adhesion/aggregation, as well as a defect in procoagulant activity. It also underlines that 
19 
 
the assumed gain-of-function mutation ORAI1 (G98S) in patient P4 is accompanied by a 
typical increase in procoagulant activity (but not in relative P5 with low SOCE). 
Furthermore, in patients carrying the FERMT3 (R573X) mutation, all platelet responses 
appeared to be more severely reduced in case of homozygosity than of heterozygosity. 
This may be of clinical relevance, since only the homozygous carrier P7 had a history of 
bleeding (see Table 1). 
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Subject(s) Mutation Platelet count MPV Hematocrit Clinical history 
  (x 10
9
/L) (fL) (L/L)  
HC1-12 (home C) None assumed 166-390 9.1-12.1 0.36-0.49 None 
C1-5 (travel C) None assumed 156-291 9.0-11.6 0.36-040 None 
P1 (child) ORAI1 (R91W) W/W 207 n.d. 0.41 Immunodeficiency, myopathy, 
anhydrosis 
P1 (BM) BM transplanted 74
+
 8.9
+
 0.23
+
 Thrombocytopenia, stabilized 
myopathy 
P2 (mother P1) ORAI1 (R91W) R/W 115
+
 8.8
+
 0.36 Mild thrombocytopenia 
P3 (father P1) ORAI1 (R91W) R/W 156
+
 9.2 0.32
+
 No known history of bleeding 
P4 (child) ORAI1 (G98S) G/S 114
+
 7.7
+
 0.34
+
 Thrombocytopenia (recurrent), 
myopathy with tubular 
aggregates, anhydrosis 
P5 (mother P5) ORAI1 (G98S) G/S 70
+
 9.2 0.37 Thrombocytopenia, myopathy 
with tubular aggregates, 
anhydrosis 
P6 (adult) STIM1 (R429C) R/C 150 n.d. n.d. No known history of bleeding 
P7 (child) FERMT3 (R573X) X/X 182 7.5
+
 0.31
+
 Immunodeficiency, severe 
vaginal bleeding, leukocytosis 
P7 (BM) BM transplanted 168 6.0
+
 0.33
+
 No known clinical symptoms 
P8 (father P7) FERMT3 (R573X) R/X 126
+
 8.3 0.42 No known history of bleeding 
P9 (mother P7) FERMT3 (R573X) R/X 142
+
 6.8
+
 0.39 No known history of bleeding 
+ Outside of normal range 
Table 1. Subject characteristics. Abbreviations: MPV, mean platelet volume; n.d., not 
determined. 
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Subject Mutation SOCE Sum Phase1 Phase2 Phase3 
HC1-12 None o 0 0.00 0.00 0.00 
C1-6 None o -1 0.00 0.00 -0.33 
P1 ORAI1 (R91W) W/W -- -10 -0.50 -0.17 -1.00 
P2 ORAI1 (R91W) R/W -- -8 -0.42 -0.17 -0.67 
P3 ORAI1 (R91W) R/W - -10 -0.50 -0.33 -0.67 
P4 ORAI1 (G98S) G/S o -4 -0.50 0.00 0.67 
P5 ORAI1 (G98S) G/S - -13 -0.83 -0.33 -0.33 
P7 FERMT3 (R573X) X/X n.d. -21 -1.00 -1.00 -1.00 
P8 FERMT3 (R573X) R/X n.d. -14 -0.50 -0.83 -1.00 
P9 FERMT3 (R573X) R/X n.d. -12 -0.42 -0.83 -0.67 
  
Table 2. Overall comparison of defective SOCE and impairment in thrombus 
formation of individual patients. For indicated patients, measurements of SOCE (see 
Figure 2) and differential heatmap data relative to control cohort HC1-12 (see Figure 5C) 
were tabled to obtain an overview of the changes in platelet function. For thrombi (1600 
s-1) formed on the three microspots (Sp1-3), all parameters (V1-7) were scored as within 
normal range (0), decreased (-1) or increase (+1). Per patient, summed scores are 
indicated (column 'Sum'). In addition, fractions of altered scores are indicated for three 
phases of thrombus formation. Phase 1 refers to platelet adhesion and aggregation 
(Sp1-3, V1-4), phase 2 to platelet integrin activation and granule secretion (Sp1-3, V6-
7), and phase 3 to platelet procoagulant activity (Sp1-3, V5). 
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Legends to figures 
 
Figure 1. Defective Ca2+ entry in platelets from a patient with a homozygous R91W 
mutation in ORAI1. Fura-2-loaded platelets from patient P1 (ORAI1W/W) and travel 
control C1 were used, suspended in Hepes buffer with 0.1 mM EGTA. Rises in cytosolic 
Ca2+ were measured in time upon stimulation with convulxin (Cvx, 50 ng/mL), thrombin 
(Thr, 4 nM) or thapsigargin (Thaps, 1.0 µM). After a defined time, CaCl2 (2 mM) was 
added to induce Ca2+ entry. Representative traces (A) and quantification (B) of Ca2+ 
increases in platelets from control subject and patient P1. Note that the maximal Ca2+ 
rise in response to CaCl2 following thapsigargin was used as a measure of SOCE 
capacity. 
 
Figure 2. Variably defective Ca2+ entry in platelets from patients with ORAI1W/W, 
ORAI1G/S or STIM1R/C mutations. Fura-2-loaded platelets in Hepes buffer with 0.1 mM 
EGTA were stimulated with thapsigargin (1.0 µM), and after a defined time with CaCl2 (2 
mM). Platelets were analyzed from 12 healthy home controls (HC1-12), 6 healthy travel 
controls (C1-6), and the indicated patients/relatives (P1-6). Platelets from patient P1 
were also analyzed after bone marrow (BM) transplantation. Shown are maximal 
increases in Ca2+. Dotted lines indicate range of SOCE levels (CaCl2-induced Ca2+ rise 
after thapsigargin) for platelets from home controls (mean ± SD, for HC1-12).  
 
Figure 3. Defective Ca2+ entry in platelets from a patient with a heterozygous 
R429C mutation in STIM1. Fura-2-loaded platelets from patient P6 (STIM1R/C) and 
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travel control C6, suspended in Hepes buffer with 0.1 mM EGTA, were stimulated with 
convulxin (Cvx, 50 ng/mL), thrombin (Thr, 4 nM) or thapsigargin (Thaps, 1.0 µM), after 
which CaCl2 (2 mM) was given to induce Ca2+ entry. Representative traces (A) and 
quantification (B) of Ca2+ rises in platelets from control subject and patient P6. 
 
Figure 4. Altered thrombus formation of blood from patients with ORAI1W/W, 
ORAI1G/S or STIM1R/C mutations. Whole blood from indicated control subjects and 
patients was perfused over three microspots (Sp1, collagen type I; Sp2, 
VWF/rhodocytin; Sp3, VWF/fibrinogen; downstream → upstream ) at wall-shear rate of 
1600 s-1. After 3.5 min of perfusion, brightfield images were taken from thrombi on all 
microspots, and platelets were stained for PS exposure (AF568-annexin A5), P-selectin 
expression (AF647 anti-CD62P mAb), and integrin αIIbβ3 activation (FITC anti-fibrinogen 
mAb). Shown are representative brightfield and fluorescence images at spot 1, obtained 
with blood from control C2 and patients P1, P4 and P6 (bars, 50 µm). 
 
Figure 5. Integrated analysis of thrombus formation for patients with ORAI1, 
STIM1 or FERMT3 mutations. Thrombus formation on three microspots was measured 
with blood from home controls (HC1-12), travel controls (C1-6) and indicated 
patients/relatives with a genetic mutation in ORAI1 (P1-5), STIM1 (P6) or FERMT3 (P7-
9), at wall-shear rate of 1600 s-1, as for Figure 4. Coding of microspots: Sp1, collagen 
type I; Sp2, VWF/rhodocytin; Sp3, VWF/fibrinogen. Coding of outcome parameters: V1, 
thrombus morphological score (scale 0-5); V2, platelet surface area coverage (% SAC); 
V3 thrombus contraction score (scale 0-3); V4, thrombus multilayer score (scale 0-3); 
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V5, PS exposure (% SAC); V6, P-selectin expression (% SAC); V7, αIIbβ3 activation (% 
SAC). Data were scaled per parameter from 0-10. (A) Heatmap of scaled values for 
control groups HC1-12 and C1-6 (means); and of scaled values for individual patients (*) 
and relatives. (B) Subtraction heatmap of scaled values, compared to those from HC1-
12. (C) Subtraction heatmap after filtering for differences considered to be relevant, i.e. 
outside the range of mean ± 2 SD (HC1-12). 
 
Figure 6. Altered thrombus formation after bone marrow transplantation. 
Thrombus formation (1600 s-1) on three microspots measured with blood from indicated 
home controls (HC1-12), travel controls (C1-6) and two patients P1 (ORAI1W/W) and P7 
(FERMT3R/X), both before (*) and after bone marrow transplantation (BMT). For 
description of microspots and parameters, as for Figure 4. Subtraction heatmap of 
scaled values after filtering for differences considered to be relevant, i.e. outside the 
range of mean ± 2 SD (HC1-12). 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 6. 
 
